

"Requested" H.S. 6/28/2010

**BARNES & THORNBURG** LLP  
btlaw.com

11 South Meridian Street  
Indianapolis, Indiana 46204-3535  
(317) 236-1313

Fax Number: (317) 231-7433

**FAX COVER SHEET**

	NAME	COMPANY NAME	FACSIMILE NO.
TO:	Examiner Hong Sang	USPTO	1-571-273-8145

FROM: Eric E. Williams

DIRECT DIAL: 317-231-6410

E-MAIL: eric.williams@btlaw.com

DATE: June 28, 2010

TIME SENDING: \_\_\_\_\_

NUMBER OF PAGES (INCLUDING THIS COVER SHEET): 8

If you have difficulty receiving this Fax, please call Barnes &amp; Thornburg at (Resource Center) 317-231-7495 and ask for \_\_\_\_\_

Dear Examiner Sang:

Transmitted herewith is a revised claim set with proposed amendments per our teleconference on Monday, June 28, 2010. We look forward to hearing from you later this week regarding these proposed amendments.

Response once received: Please deliver immediately.

CLIENT# 51284  
MATTER# 212664

☐ Original to follow by mail  
☒ Original will not follow by mail

**CONFIDENTIALITY NOTICE:** This message is for the exclusive use of the individual or entity to which it is addressed and is confidential. If you are not the addressee or an employee or agent of the addressee responsible for delivering it to the addressee, please do not read, use, disclose, copy or distribute this message and do not take any action in reliance upon it. If you have received this message in error, please notify us immediately by telephone (collect) to arrange for its return. We do not intend to waive any attorney-client or work product privilege by the transmission of this message.

Atlanta Chicago Indiana Michigan Minneapolis Ohio Washington, D.C.

**CLAIM LIST**

U.S. Patent Application Serial No. 10/801,517

Our File: 51284-212664

1. (currently amended) A composition comprising  
a phospholipid, wherein the phospholipid is dioleoylphosphatidylserine (DOPS),  
an isolated saposin C-related polypeptide, wherein the polypeptide is selected from the  
group consisting of: (a) a polypeptide having ~~[[an]]~~ the amino acid sequence at least 95 percent  
identical to the entire length of SEQ ID NO: 2; and (b) a polypeptide having ~~[[an]]~~ the amino  
acid sequence identical to SEQ ID NO: 2; and  
a pharmaceutically acceptable carrier;  
wherein the polypeptide retains plasma membrane affinity;  
wherein the phospholipid forms a nanovesicle incorporating the polypeptide;  
and wherein the nanovesicle incorporating the polypeptide exhibits anti-tumor activity.
2. (canceled)
3. (canceled)
4. (previously presented) The composition of claim 1, wherein the molar ratio of  
the polypeptide to the phospholipid is in the range from about 1:1 to about 1:50.
5. (previously presented) The composition of claim 1, wherein the molar ratio of  
the polypeptide to the phospholipid is in the range from about 1:1 to about 1:10.
6. (currently amended) The composition of claim 1 wherein the composition is  
capable of inducing apoptosis in hyper-proliferating cells, wherein the hyper-proliferating cells  
are ~~selected from the group consisting of tumor cells and cancer cells.~~
7. (previously presented) The composition of claim 1, wherein the polypeptide  
comprises at least 25 contiguous amino acids of SEQ ID NO: 2.
8. (previously presented) The composition of claim 1, wherein the mass ratio  
of the polypeptide to the phospholipid is in the range from about 15:1 to about 3:10.
9. (withdrawn; currently amended) A method for modulating the distribution  
of an inner leaflet component in a plasma membrane of a hyper-proliferating cell of a  
subject comprising administering to the subject a therapeutically effective amount of the  
composition of claim 1;  
wherein the inner leaflet component is phosphatidylserine; and

U.S. Application Serial No. 10/801,517  
Supplemental Response: June 23, 2010

wherein the hyper-proliferating cell is ~~selected from the group consisting of a tumor cell and a cancer cell.~~

10. (canceled)

11. (withdrawn; previously presented) The method of claim 9, wherein the phosphatidylserine is dioleoylphosphatidylserine.

12. (withdrawn; previously presented) The method of claim 9, wherein the distribution of the inner leaflet component in the outer leaflet of the plasma membrane is altered.

13. (withdrawn; previously presented) The method of claim 9, wherein the concentration of the inner leaflet component in the outer leaflet is increased.

14. (canceled)

15. (canceled)

16. (withdrawn; previously presented) The method of claim 9, wherein the method promotes cell death of the hyper-proliferating cell.

17. (withdrawn; previously presented) A method of modulating tumor volume in a subject, the method comprising administering a therapeutically effective amount of the composition of claim 1.

18. (withdrawn; currently amended) The method of claim 17, wherein the composition promotes cell death in hyper-proliferating cells, wherein the hyper-proliferating cells are ~~selected from the group consisting of tumor cells and cancer cells.~~

19. (canceled)

20. (withdrawn; previously presented) The method of claim 18, wherein the cancer cells are selected from the group consisting of sarcoma, neuroblastoma, breast carcinoma, and squamous cell carcinoma cells.

21. (canceled)

22. (canceled)

23. (withdrawn; previously presented) The method of claim 17, wherein the subject is a mammal.

24. (withdrawn; previously presented) The method of claim 23, wherein the

U.S. Application Serial No. 10/801,517  
Supplemental Response: June 23, 2010

mammal is a human.

25. (withdrawn; previously presented) The method of claim 17, wherein the tumor volume decreases.

26. (withdrawn; previously presented) The method of claim 17, wherein the molar ratio of the polypeptide to the phospholipid is in the range from about 1:1 to about 1:50.

27. (withdrawn; previously presented) The method of claim 26, wherein the molar ratio of the polypeptide to the phospholipid is in the range from about 1:1 to about 1:10.

28. (canceled)

29. (withdrawn; previously presented) A method of treating a cancer in a subject, the method comprising administering a therapeutically effective amount of the composition of claim 1.

30. (canceled)

31. (canceled)

32. (withdrawn; previously presented) The method of claim 29, wherein the molar ratio of the polypeptide to the phospholipid is in the range from about 1:1 to about 1:50.

33. (withdrawn; previously presented) The method of claim 32, wherein the molar ratio of the polypeptide to the phospholipid is in the range from about 1:1 to about 1:10.

34. (canceled)

35. (withdrawn; currently amended) The method of claim 29, wherein the composition promotes cell death in hyper-proliferating cells, wherein the hyper-proliferating cells are ~~selected from the group consisting of tumor cells and cancer cells.~~

36. (withdrawn; previously presented) The method of claim 35, wherein the cell death occurs through apoptosis.

37. (canceled)

38. (withdrawn; previously presented) The method of claim 35, wherein the cancer cells are selected from the group consisting of sarcoma, neuroblastoma, breast carcinoma, and squamous cell carcinoma cells.

39. (withdrawn; previously presented) The method of claim 29, wherein the subject is a mammal.

U.S. Application Serial No. 10/801,517  
Supplemental Response: June 23, 2010

40. (withdrawn; previously presented) The method of claim 39, wherein the mammal is a human.

41. (withdrawn; previously presented) The method of claim 29, wherein the composition is administered enterally, parenterally, subcutaneously, intravenously, intraperitoneally, or topically.

42. (withdrawn; previously presented) The method of claim 29, wherein multiple doses of the composition are administered to the subject.

43. (withdrawn; previously presented) The method of claim 29, wherein a single dose of the composition is administered to the subject.

44. (currently amended) An anti-tumor agent comprising a nanovesicle prepared by (a) preparing a composition that comprises (i) a dried inner leaflet component, wherein the inner leaflet component is a phospholipid, wherein the phospholipid is dioleoylphosphatidylserine (DOPS) and (ii) a dried and isolated prosaposin-related polypeptide;

wherein the polypeptide has an amino acid sequence selected from the group consisting of the amino acid sequence set forth in SEQ ID NO: 1, the amino acid sequence that is at least 95 percent identical to the entire length of SEQ ID NO: 1, the amino acid sequence set forth in SEQ ID NO: 2, and the amino acid sequence that is at least 95 percent identical to the entire length of SEQ ID NO:2 and wherein the polypeptide retains plasma-membrane affinity;

wherein the molar ratio of the polypeptide to the dioleoylphosphatidylserine in the composition is in the range from 1:1 to 1:25;

in a pharmaceutically acceptable carrier;

(b) treating the composition to form a nanovesicle;

wherein the nanovesicle formed has a diameter in the range 10 to 800 nm;

and wherein the composition is capable of inducing apoptosis in hyper-proliferating cells, wherein the hyper-proliferating cells are ~~selected from the group consisting of tumor cells and~~ cancer cells.

45. (previously presented) The anti-tumor agent of claim 44, wherein the mass ratio of the polypeptide to the dioleoylphosphatidylserine is approximately 5:1.

46. (previously presented) The anti-tumor agent of claim 44, wherein the mass

U.S. Application Serial No. 10/801,517  
Supplemental Response: June 23, 2010

ratio of the polypeptide to the dioleoylphosphatidylserine is approximately 15:7.

47. (previously presented) The anti-tumor agent of claim 44, wherein the mass ratio of the polypeptide to the dioleoylphosphatidylserine is in the range from about 15:1 to about 3:10.

48. (previously presented) The anti-tumor agent of claim 44, comprising approximately 10  $\mu$ M polypeptide and approximately 30  $\mu$ M dioleoylphosphatidylserine.

49. (previously presented) The anti-tumor agent of claim 44, comprising approximately 10  $\mu$ M polypeptide and approximately 70  $\mu$ M dioleoylphosphatidylserine.

50. (currently amended) A composition consisting essentially of an anionic phospholipid nanovesicle consisting of dioleoylphosphatidylserine (DOPS) embedded with a biologically active saposin C-related polypeptide, wherein the polypeptide comprises [[an]] the amino acid sequence that has at least 95% sequence identity to the amino acid sequence of the entire length of SEQ ID NO:2; and a pharmaceutically acceptable carrier; wherein the phospholipid nanovesicle exhibits anti-tumor activity.

51. (canceled)

52. (canceled)

53. (previously presented) The composition of claim 50, wherein the molar ratio of the polypeptide to the phospholipid is in the range from about 1:1 to about 1:50.

54. (previously presented) The composition of claim 50, wherein the molar ratio of the polypeptide to the phospholipid is in the range from about 1:1 to about 1:10.

55. (currently amended) The composition of claim 50 wherein the composition is capable of inducing apoptosis in hyper-proliferating cells upon contact, wherein the hyper-proliferating cells are ~~selected from the group consisting of tumor cells and cancer cells.~~

56. (canceled)

57. (canceled)

58. (withdrawn; currently amended) A process for the manufacture of a pharmaceutical agent comprising the steps of:

(a) preparing a composition that comprises (i) an inner leaflet component, wherein the inner leaflet component is a phospholipid, wherein the phospholipid is dioleoylphosphatidylserine (DOPS) and (ii) a prosaposin-related polypeptide, wherein the

U.S. Application Serial No. 10/801,517  
Supplemental Response: June 23, 2010

polypeptide is selected from the group consisting of: (a) a polypeptide having the amino acid sequence at least 95 percent identical to the entire length of SEQ ID NO: 2; and (b) a polypeptide having the amino acid sequence identical to SEQ ID NO: 2 and wherein the polypeptide retains plasma-membrane affinity;

in a pharmaceutically acceptable carrier;

(b) treating the composition to form a nanovesicle;

wherein the nanovesicle formed exhibits anti-tumor activity.

59. (currently amended) A pharmaceutical agent comprising nanovesicles prepared by

(a) preparing a composition that comprises (i) an inner leaflet component, wherein the inner leaflet component is dioleoylphosphatidylserine (DOPS) and (ii) a prosaposin-related polypeptide;

wherein the polypeptide has an amino acid sequence selected from the group consisting of the amino acid sequence set forth in SEQ ID NO: 1, the amino acid sequence that is at least 95 percent identical to the entire length of SEQ ID NO: 1, the amino acid sequence set forth in SEQ ID NO: 2, and the amino acid sequence that is at least 95 percent identical to the entire length of SEQ ID NO:2 and wherein the polypeptide retains plasma-membrane affinity;

in a pharmaceutically acceptable carrier;

(b) treating the composition to form a nanovesicle;

wherein the nanovesicle formed exhibits anti-tumor activity.

60. (canceled)

61. (canceled)

62. (previously presented) The pharmaceutical agent of claim 59, wherein the molar ratio of the polypeptide to the dioleoylphosphatidylserine (DOPS) is in the range from about 1:1 to about 1:50.

63. (previously presented) The pharmaceutical agent of claim 59, wherein the nanovesicle has a diameter in the range 0.01 to 1  $\mu\text{m}$ .

64. (withdrawn; currently amended) A process for the manufacture of a pharmaceutical agent comprising the steps of:

U.S. Application Serial No. 10/801,517  
Supplemental Response: June 23, 2010

(a) preparing a composition that comprises (i) a dried inner leaflet component, wherein the inner leaflet component is dioleoylphosphatidylserine and (ii) a dried and isolated prosaposin-related polypeptide, wherein the polypeptide is selected from the group consisting of: (a) a polypeptide having [[an]] the amino acid sequence at least 95 percent identical to the entire length of SEQ ID NO: 2; and (b) a polypeptide having [[an]] the amino acid sequence identical to SEQ ID NO: 2 and wherein the polypeptide retains plasma-membrane affinity;

wherein the molar ratio of the polypeptide to the inner leaflet component in the composition is in the range from 1:1 to 1:25;

in a pharmaceutically acceptable carrier;

(b) treating the composition to form a nanovesicle;

wherein the nanovesicle formed has a diameter in the range 10 to 800 nm and exhibits anti-tumor activity.

65. (currently amended) A pharmaceutical agent comprising nanovesicles prepared by

(a) preparing a composition that comprises (i) a dried inner leaflet component, wherein the inner leaflet component is dioleoylphosphatidylserine (DOPS) and (ii) a dried and isolated prosaposin-related polypeptide;

wherein the polypeptide has an amino acid sequence selected from the group consisting of the amino acid sequence set forth in SEQ ID NO: 1, the amino acid sequence that is at least 95 percent identical to the entire length of SEQ ID NO: 1, the amino acid sequence set forth in SEQ ID NO: 2, and the amino acid sequence that is at least 95 percent identical to the entire length of SEQ ID NO:2 and wherein the polypeptide retains plasma-membrane affinity;

wherein the molar ratio of the polypeptide to the inner leaflet component in the composition is in the range from 1:1 to 1:25;

in a pharmaceutically acceptable carrier;

(b) treating the composition to form a nanovesicle;

wherein the nanovesicle formed has a diameter in the range 10 to 800 nm and exhibits anti-tumor activity.